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SUMMARY
The data of two cohort studies of HIV-infected individuals were used to examine whether the
rate of CD4 decline is a determinant of HIV progression, independent of the most recent CD4
count. Time from seroconversion to clinical AIDS was the main outcome measure. Rates of
CD4 decline were estimated using the ordinary least squares regression method. AIDS
incidences were compared in individuals who had previously experienced either a steeper or a
less steep rate of CD4 decline. Cox proportional hazards model including a time-dependent
covariate for the rate of CD4 decline was performed. The rate of prior CD4 decline was
signi®cantly associated with the risk of developing AIDS independently from the most recent
CD4 count, with a 2% increase in hazard of AIDS (P!0±01) for a diﬀerence of 10 cells}mm$
in the estimated yearly drop in CD4 count. This ®nding gives scienti®c credit to the belief that
individuals with a prior steeper CD4 decline consistently have a higher subsequent risk of
developing AIDS than those with a less steep prior decline.
INTRODUCTION
Despite reports that plasma viral load strongly
predicts progression to AIDS and death, the CD4
lymphocyte count remains an important marker for
short term predictions of the risk of AIDS of death in
HIV-infected individuals [1±5]. Previous studies have
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shown that if the CD4 count is known, the time from
seroconversion seems to be of little additional value
when assessing the risk of progression to AIDS [6, 7].
A recent report from the Multicenter AIDS Cohort
Study (MACS) con®rmed these results using re-
gression modelling [8]. These ®ndings would suggest
that prior rate of CD4 decline may not add much
prognostic information if the current CD4 count is
known. However, whilst time from seroconversion
certainly correlates with the rate of CD4 decline, it
only provides information as to the probable history
of CD4 decay. Models which incorporate accurate
estimates of such a decline are needed to answer to the
question: `given a certain level of CD4 count, is there
a diﬀerential risk of developing AIDS according to
individuals' previous pattern of CD4 decline ?' and if
so to quantify this eﬀect. Some authors either assumed370 A. Cozzi Lepri and others
or showed that the most recent CD4 count is suﬃcient
for predicting a diagnosis of AIDS [9±11]. In contrast,
it has been suggested that the underlying pattern of
CD4 decline may provide a more powerful indicator
for HIV disease progression than the CD4 count itself
[12±15]. Saah and colleagues [13] found that the
decline in the CD4 count during the ®rst 6 months of
follow-up was associated with the risk of developing
AIDS independently from the CD4 percentage and
recently Che # ne and colleagues [14]showed that among
patients whose CD4 count reached 50 cells}mm$ a
steeper prior rate of CD4 decline was associated with
a poorer survival independently from the actual CD4
count. In contrast, Yong and colleagues [15] reported
that individuals who have a low CD4 count for a
period of 6 months have higher immediate risk of
AIDS than individuals who have just decreased to
that level from a higher level 6 months earlier.
In this study we used the data of the Italian
Seroconversion Study Cohort (ISSC) and those of the
Royal Free Hospital Haemophilia Cohort (RFHHC)
of HIV-infected haemophilic individuals to determine
whether the rate of CD4 decline is a determinant of
HIV progression, independent of the most recent CD4
count. The use of both cohorts allowed the issue to be
addressed in individuals who became infected through
all the main modes of HIV transmission; i.e. injecting
drug use, sexual contacts and receipt of contaminated
blood products.
METHODS
Details of the ISSC and RFHHC have been fully
described elsewhere [16, 17]. In brief, the ISSC
includes 1292 HIV-infected individuals with a docu-
mented negative test for HIV followed by a con®rmed
positive test within 2 years. It is an ongoing study in
16 centres and includes individuals who acquired HIV
by sharing needles or through sexual contact. The
RFHHC consists of 111 men with haemophilia
infected with HIV during 1979±85 after treatment
with contaminated blood products. Retrospective
testing of stored serum samples and the introduction
of sterilized blood products in 1985, have enabled the
seroconversion dates to be estimated with a maximum
error of 2 years for 83 (74±8%) of individuals.
In addition to demographic information such as
gender and age, full clinical examinations and
measures of CD4 lymphocyte count were conducted
about every 6 months in both cohorts; regular
monitoring of CD4 count started in 1982. CD4 subset
studies were performed by ¯ow-cytometry, using
standardized techniques (Ortho diagnostics, Raritan,
New Jersey, USA and Becton Dickinson, Crowley,
UK for ISSC and RFHHC respectively).
The Italian AIDS surveillance registry and census
bureau were used to minimize loss to follow up and to
check vital status of individuals enrolled in the ISSC
whose last clinical visit was at least 2 years before 31
July 1995. Clinical Status was known on all members
of the RFHHC up to 1 January 1996.
Study population
Nine hundred and eighty-three individuals of the
ISSC and 103 of the RFHHC with at least three CD4
measurements,forwhomwecouldaccuratelyestimate
the rate of CD4 decline, were included in the analysis.
Statistical analysis
A clinical diagnosis of AIDS according to the
European Center for Diseases Control de®nition in
use at the time of the event occurring [17, 18] was the
main endpoint of the analysis. To evaluate the
in¯uence of the rate of CD4 decline on the course of
HIV progression, incidence rates of developing AIDS
(per 1000 person-years) after an individual had
reached a certain pre-de®ned CD4 level (300, 200 and
100 cells}mm$) were calculated. Incidence rates were
compared in individuals who had a `steeper' or `less
steep' estimated rate of CD4 decline prior to their
CD4 count falling below the cut-oﬀ level. The time
point t at which an individual was estimated to decline
below a given CD4 count level was determined by
linear interpolation between the ®rst count below that
level and the previous count. In de®ning the rate of
CD4 count decline prior to the date of reaching this
cut-oﬀ, we considered the ordinary least square
estimates of the slopes calculated over the previous 5
years before t. Individuals were divided into `slow
decline' or `fast decline' if their estimated slope was
below (less steep) or above (steeper) the median
population slope. This was possible only for patients
with at least two CD4 counts over the previous 5 years
before t.
For the ISSC data, AIDS-free time was calculated
as the time from seroconversion to AIDS diagnosis
for those who developed AIDS and the time from
seroconversion to 31 July 1995 for those without an
AIDS diagnosis. AIDS-free time for individuals in the
RFHHC was calculated as the time from sero-
conversion to AIDS diagnosis or 31 December 1995
whichever happened ®rst. Follow-up times of indi-
viduals who died before developing AIDS were371 The rate of CD4 decline
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Fig. 1. Calculation of a time-dependent estimate for the rate of CD4 count decline in one individual. The slope coeﬃcient
of the regression line ®tted using CD4 counts measured up to time tj (j¯3, 4, 5) gives the estimate of the rate of CD4 count
decline at time tj.
censored at the date of death. A standard Cox
proportional hazards model was used for the multi-
variate analysis. The model included time-dependent
covariatesforthemostrecentCD4count,theprevious
rate of CD4 count decline and the antiretroviral
treatment usage. The covariate expressing the treat-
ment usage was a time dependent indicator taking the
value zero until the point in time when the individual
®rst received antiretroviral treatment and 1 thereafter.
Treatment was included in the model on an `intention
to treat' basis (i.e. the covariate remained set to one
irrespective of whether the patient stopped treatment).
This was done because antiretroviral therapy has been
shown to aﬀect the CD4 count and to delay the onset
of AIDS [18±21]. Antiretroviral treatment included
treatment with zidovudine (ZDV), didanosine (ddl) or
zalcitabine (ddC) (mainly monotherapy). Age at
seroconversion was also included since its association
with progression to AIDS is well established [22, 23].
In the Cox regression the previous rate of CD4 decline
was estimated by least squares regression for each
individual using the CD4 counts measured up to the
most recent time point (see below).
A time dependent covariate for the estimated rate of
CD4 decline
A new CD4 count had the eﬀect of changing both the
most recent value for the CD4 count and the estimate
of the rate of decline in the model. Thus, for example,
if an individual had 600, 500, 500, 350 and 200 cells}
mm$ at yearly-spaced times t"±t&, respectively, the
covariate containing the value for the slope would be
missing at times t" and t# (three measurements was the
requiredconditionforasuﬃcientlyaccurateestimate),
®50 at time t$, ®75 at time t%, and ®95 at time t&
(Fig. 1). Initially the slopes were estimated using all
the CD4 counts collected since the estimated date of
seroconversion. As a further analysis only those
collected over the last 5 years (for those with at least
2 CD4 count over the last 5 years of follow-up) were
included in the slope calculations. To test the
hypothesis of a diﬀerential eﬀect of the rate of CD4
decline according to the level of CD4 count (inter-
action between the rate of decline and the most
recent CD4 count), variables containing the estimated
rate of CD4 decline when the CD4 count was included
in pre-de®ned bands (e.g. !100, 100±300 and
300±500 cells}mm$) were added to the model. Similar
results were found whichever pre-de®ned bands were
chosen. For convenience, all the analyses were
performed using the untransformed scale for the CD4
count, the conclusions being similar when the log-
arithmic scale for the CD4 count or the square root
scale for calculating the slopes of CD4 count decline
were used. All statistical analyses were carried out
using Statistical Analysis Software (SAS) [24].
RESULTS
A description of the study populations according to
gender,modeoftransmission,antiretroviraltreatment372 A. Cozzi Lepri and others
Table 1. Description of the ISSC and RFHHC study populations*
ISSC RFHHC
Number Per cent Number Per cent
Gender
Male 693 70±5 103 100±0
Female 290 29±5Ð Ð
Mode of transmission
Injecting drug use 498 50±7Ð Ð
Homosexual contacts 281 28±6Ð Ð
Heterosexual contacts 187 19±0Ð Ð
Blood products recipient Ð Ð 103 100±0
Other 17 1±7Ð Ð
Antiretroviral treatment
Yes 495 50±45 9 5 7 ± 3
No 488 49±65 1 4 2 ± 7
AIDS
Yes 213 21±74 9 4 7 ± 6
No 770 78±35 8 5 2 ± 4
Median (range) Median (range)
Age at seroconversion (years) 27 (14±66) 21 (2±62)
Follow-up time (years) 5±21 (0±87±14±37) 12±77 (3±01±16±18)
Number of CD4 count measurements 7 (3±28) 26 (3±75)
* Only individuals with at least 3 measurements of CD4 count.
 ZDV, ddl, ddC (mainly monotherapy).
 Calculated as the time to death for the individuals who died or the time to the date of cut-oﬀ of the study for those still
alive.
Table 2. Risk of AIDS (calculated as rates per 1000 person years) according to the level of CD4 count in
individuals who experienced either a steeper or less steep rate of CD4 count decline (estimated using ordinary
least squares method) over the 5 years prior to the CD4 count falling below the cut-oﬀ level
ISSC
Current CD4 count (cells}mm$)
RFHHC
Current CD4 count (cells}mm$)
300 200 100 300 200 100
Median prior drop
(cells}mm$ per year) 79 93 94 70 63 72
Rate of CD4 decline
!median (less steep)
Number 191 156 97 26 32 22
AIDS 10 25 41 12 18 11
Person-years (pyrs) 4722±5 2958±8 1015±3 1134±4 964±9 418±7
Rate (per 1000 pyrs) 2±12 8±45 40±38 10±58 18±65 26±27
&median (steeper)
Number 191 157 98 26 32 22
AIDS 19 35 45 14 21 18
Person-years (pyrs) 4865±1 2820±1 886±6 1183±4 1029±2 440±5
Rate (per 1000 pyrs) 3±91 12±41 50±76 11±83 20±41 40±86
Total
Number 382 313 195 52 64 44
Relative rate 1±84 1±47 1±26 1±12 1±09 1±56
(95% CI) (0±82±4±44) (0±85±2±56) (0±81±1±97) (0±48±2±65) (0±55±2±18) (0±70±3±65)373 The rate of CD4 decline
Table 3. Relative hazards of developing AIDS from ®tting a Cox model with a time dependent covariate for
the estimated slopes in the ISSC
Relative hazards of AIDS (95% CI)
Covariates Crude Adjusted*
All CD4 counts since the date of SC
Most recent CD4 count
(per 100 cells}mm$ lower)
1±830 (1±682±1±992)
P¯0±0001
1±783 (1±600±1±986)
P¯0±0001
Rate of CD decline
(per 10 cells}mm$ diﬀerence in yearly drop)
1±028 (1±019±1±036)
P¯0±0001
1±022 (1±009±1±035)
P¯0±0006
CD4 counts over the previous 5 years
Most recent CD4 count
(per 100 cells}mm$ lower)
1±830 (1±682±1±992)
P¯0±0001
1±779 (1±597±1±981)
P¯0±0001
Rate of CD4 decline
(per 10 cells}mm$ diﬀerence in yearly drop)
1±028 (1±020±1±037)
P¯0±0001
1±024 (1±011±1±036)
P¯0±0002
* Adjusted estimates refer to the model comprising the most recent CD4 count, the ordinary least squares estimates of the
slope of CD4 decline, age and treatment usage.
usage and AIDS cases is given in Table 1. The median
and range of age at seroconversion, length of follow
up, and number of CD4 count measurements are also
reported. All patients in the RFHHC seroconverted
during 1979±85. As a result, patients in this cohort
had a longer follow-up and more CD4 measurements,
on average, than those in the ISSC which includes
seroconversions up to July 1995. A higher proportion
of AIDS cases was also observed in the RFHHC as a
result.
Table 2 shows the risk of AIDS, calculated as rates
per 1000 person-years (pyrs), conditioning on the level
of current CD4 count in individuals who experienced
either a less steep or a steeper rate of CD4 decline over
the previous 5 years. It is clear from this table that the
risk of AIDS strongly increases as individuals reach
lower levels of the current CD4 count; the risk of
AIDS for a current count of 100 cells}mm$ was 3±4
times bigger than that at 300 cells}mm$ in the
RFHHC and 13±20 times in the ISSC. Individuals
who experienced a faster decline in CD4 count over
the previous 5 years were at higher risk of developing
AIDS than those with slower prior declines at each
CD4 level (300, 200 or 100 cells}mm$). Although the
association was not signi®cant at the conventional
level of 0±05, this crude analysis performed using the
data from ISSC and from the RFHHC consistently
showed rate ratios above one when comparing the 2
groups of individuals (Table 2). So, for example, the
risk of developing AIDS for an individual in the
RFHHC with a current CD4 count of 300 cells}mm$
and having a rate of CD4 decline of 70 cells per year
or more is 12% higher than that of someone with the
same level of CD4 count but a less rapid rate of CD4
decline (!70 cells per year). Very similar results were
obtained when the slopes were calculated using the
CD4 counts observed only over the 3 years before the
pre-de®ned cut-oﬀ, which was considered as the
shortestperiodrequiredtoobtainanaccurateestimate
using the least squares method (data not shown).
Results from ®tting the Cox model con®rmed those
of the crude analysis (Tables 3, 4). The eﬀect of the
most recent CD4 count was still the most important
factor in predicting an AIDS event after adjusting for
the estimated rate of CD4 decline and the other
covariates considered (Wald v#¯110±3, P¯0±0001
and Wald v#¯33±8, P¯0±0001, in the ISSC and
RFHHC respectively). Whilst the eﬀect of the esti-
mated rate of CD4 decline was reduced after adjusting
for the most recent CD4 count it remained associated
with the outcome independently of the most recent
count, age at seroconversion and treatment usage
(Wald v#¯11±6, P¯0±0006 and Wald v#¯5±8, P¯
0±02, in the ISSC and RFHHC respectively). From the
estimated coeﬃcients a diﬀerence of 10 cells}mm$ in
theestimatedyearlydropinCD4countwasassociated
with about 2% increase in risk of AIDS, the
individuals with a faster decline being at higher risk.
The eﬀect was slightly bigger and marginally more
signi®cant when the estimates of the slope were
calculated considering the CD4 counts observed only
over the last 5 years (Tables 3, 4). As with the crude
analysis, virtually identical results were found when
considering CD4 counts observed only over the last 3
years (data not shown). To test the hypothesis of a
diﬀerent predictive value of the rate of CD4 decline
according to the most recent CD4 count, an in-
teraction term between these 2 variables has been374 A. Cozzi Lepri and others
Table 4. Relative hazards of developing AIDS from ®tting a Cox model with a time dependent covariate for
the estimated slopes in the RFHHC
Relative hazards of AIDS (95% CI)
Covariates Crude Adjusted*
All CD4 counts since the date of SC
Most recent CD4 count
(per 100 cells}mm$ lower)
1±766 (1±492±2±090)
P¯0±0001
1±809 (1±481±2±210)
P¯0±0001
Rate of CD decline
(per 10 cells}mm$ diﬀerence in yearly drop)
1±024 (1±004±1±045)
P¯0±02
1±017 (1±003±1±031)
P¯0±02
CD4 counts over the previous 5 years
Most recent CD4 count
(per 100 cells}mm$ lower)
1±766 (1±492±2±090)
P¯0±0001
1±802 (1±476±2±199)
P¯0±0001
Rate of CD4 decline
(per 10 cells}mm$ diﬀerence in yearly drop)
1±026 (1±005±1±048)
P¯0±01
1±018 (1±004±1±033)
P¯0±01
* Adjusted estimates refer to the model comprising the most recent CD4 count, the ordinary least squares estimates of the
slope of CD4 decline, age and treatment usage.
added to the initial model. Since there was no
statistical evidence for an interaction and the relative
hazards calculated at various levels of the most recent
CD4 count were very similar, the covariate expressing
the interaction eﬀect was excluded from the ®nal
model.
DISCUSSION
The results of this study clearly show that the entire
history of CD4 count contains additional prognostic
information to the most recent CD4 count. In
particular, individuals whose CD4 counts have fallen
most rapidly are those with the highest risk of AIDS
even when the current CD4 count is controlled for.
Some evidence of the existence of this eﬀect was found
when comparing the rates of developing AIDS after
an individual had reached a certain pre-de®ned CD4
level in 2 groups of individuals whose prior rate of
CD4 decline was steeper or less steep than the
population average. Whilst this was a very crude
analysis, mainly for illustrative purposes, a more
powerful analysis, involving the use of the Cox
proportional hazards model with an updated
covariate containing the continually changing es-
timate of the rate of CD4 decline, adjusted for the
continually changing most recent CD4 count, showed
that the signi®cance of the association is much higher
(P!0±01). These results are drawn from two diﬀerent
cohorts of individuals for whom an accurate estimate
of the date of seroconversion is available. Hence, it is
unlikely that our ®ndings are simply a consequence of
biases in the estimates of AIDS-free time. All the main
modes of HIV transmission (i.e. injecting drug use,
sexual contacts and receipt of contaminated blood
products) were represented across the 2 cohorts so our
results apply to all individuals irrespective of how they
acquired HIV infection. Further, results were virtually
identical when the analyses were repeated considering
death as the endpoint (data not shown).
Our ®ndings although consistent with those found
by previous studies [13±15] are in contrast with those
reported elsewhere [10, 11] that the current CD4
count alone is suﬃcient to predict future progression.
However, this discrepancy might be explained by the
diﬀerent statistical methods used. Our results also
contradict one of the assumptions of the continuous-
time Markov model [12]. However, the magnitude of
the eﬀect, after adjusting for the most recent CD4
count, is small (2% increase in risk per 100 cells}mm$
diﬀerence in yearly drop in CD4 count) compared to
the risk for 100 cells}mm$ diﬀerence in the CD4 count
(about 80% increase). Therefore, it is unlikely that
failing to incorporate this eﬀect in Markov models
would have a major eﬀect on results.
Previous studies using data from these 2 cohorts
[7, 8] and the data of the MACS [9], suggested that the
prior history of CD4 decline in a given patient could
be ignored when assessing the risk of AIDS once
his}her most recent CD4 count is known. These
studies did not, however, consider an accurate
estimate of the CD4 count decline explicitly in the
analyses and, as a result, these ®nding are not directly
comparable. For example, it is possible that 2
individuals may have the same current level of CD4375 The rate of CD4 decline
count at diﬀerent times after seroconversion simply
because their CD4 count at seroconversion was
diﬀerent while they may well have experienced the
same mean CD4 decline.
The possible biases and limitations of this study
should be mentioned before drawing ®rm conclusions.
First of all, given the lack of plasma viral load data in
these cohorts we cannot rule out the possibility that
the rate of CD4 decline is a simple surrogate of
individuals' levels of viraemia i.e. that individuals
with the steepest CD4 decline are also those with the
highest plasma viral load. It remains to be seen if the
prognostic role of the rate of CD4 decline is con®rmed
once measurements of plasma viral load are available
for these patients.
The results obtained using the Italian cohort might
be biased by the exclusion of 309 individuals of the
ISSC, 24% of the entire cohort, who had fewer than
three CD4 count measurements. These individuals are
more likely to be the faster progressors or recent
seroconverters; almost a half of these patients sero-
converted after 1990. Unfortunately, we did not have
enough CD4 measurements to calculate an accurate
estimate of their rate of CD4 decline, so we could not
assess the prognostic value of the rate of CD4 decline
in this subgroup of individuals. However, median age
and baseline CD4 count were similar in the group of
patients excluded and in those used for this analysis;
median age was 26 (range 17±59) in patients excluded
compared to 27 (range 14±66, Table 1) in the study
population and the median baseline CD4 count was
594 (range 5±1875) and 629 (range 5±1984), re-
spectively.
The usage of nucleoside monotherapy has been
shown to delay progression to AIDS and to have a
small impact on the CD4 count [18±21]. Since the
CD4 count is not a perfect surrogate for the
development of AIDS, the association between the
rate of CD4 decline and the risk of AIDS in the
individuals who received treatment might simply be a
result of bias. However, the eﬀect of prior CD4
decline remains signi®cant after adjusting for treat-
ment usage. More recently, the introduction of
protease inhibitors and treatment strategies which
include these potent drugs in combination with
nucleosides, appears to have led to reductions in the
risk of AIDS and dramatic changes in CD4 counts
following treatment [27±29]. As these patients were
followed up until the end of 1995, no patients had the
opportunity to receive these potent drug regimens.
However, it is unclear what the eﬀects of these
treatment-induced changes will have on the result of
our study and we await the opportunity to study this
issue at a later date when suﬃcient data is available
for the analysis.
While it is well established that in treatment-naõ$ve
or lightly treated patients the general underlying CD4
trend is one of monotone decay, there is no agreement
on the best explanatory model for estimating in-
dividual and population rates of CD4 count decline.
The most common assumption is that the underlying
pattern of CD4 decline is linear on the square root
scale [10, 27±30]. Even if the linear assumption (on the
raw CD4 count) may not be the `correct' model to
explain the biologic complexity of the rate of CD4
decline, in this paper we used this assumption because
we believed that it was suﬃciently successful to obtain
good `working' estimates of the rate of CD4 decline
over the relatively short term and that the actual
number of CD4 cells is more familiar to clinicians
than any other transformed ®gure. Further, we drew
the same conclusions when we repeated the analysis
using the logarithmic or the square root transform-
ation of CD4 count both for the most recent count
and for estimating the rate of decline.
When searching for pathogenic mechanisms the
relationship between the true underlying CD4 count
and the disease progression is of primary interest.
However, despite the introduction of new laboratory
methods and quality control schemes to standardize
methods, the CD4 count remains an imperfectly
measured marker and the observed relationship
between the measured CD4 count and HIV pro-
gression may not be the same as the relationship
between the underlying CD4 trend and the disease.
In conclusion, these data provide evidence that the
rate of CD4 decline provides additional prognostic
information which is not contained in the most recent
CD4 count. Whilst the eﬀects reported are relatively
small and, as such, are unlikely to dramatically alter
clinical decisions, our study recognised the predicting
role of the rate of CD4 decline, a re®ning step in the
process of de®ning markers of HIV progression.
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